AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23301779 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity resistance exercise (4 sets, 8-10 repetitions/set, 65-70% 1RM)
Number of subjects: 10
Study 23301779 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity resistance exercise (4 sets, 4-6 repetitions/set, 85-90% 1RM)
Number of subjects: 10
Study 23301779 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 10
Study 21519814 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week schedule of gemcitabine (1000 mg/m² as a 30-min infusion weekly for 3 consecutive weeks every 4 weeks)
Number of subjects: 90
Study 21519814 — intervention group
Group type: COMPARATOR
Intervention: 3-week schedule of gemcitabine (1000 mg/m² as a 30-min infusion weekly for 2 consecutive weeks every 3 weeks)
Number of subjects: 90
Study 18821031 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of patient-reported outcomes (PROs) in clinical practice
Number of subjects: 0
Study 18821031 — intervention group
Group type: COMPARATOR
Intervention: Conventional individual patient trials
Number of subjects: 0
Study 16549639 — intervention group
Group type: EXPERIMENTAL
Intervention: Total homocysteine (tHcy) measured in tertiles (<14.7, 14.7 to 19.5, > or =19.6 micromol/L)
Number of subjects: 840
Study 16549639 — intervention group
Group type: EXPERIMENTAL
Intervention: Total homocysteine (tHcy) adjusted for GFR
Number of subjects: 840
Study 16549639 — intervention group
Group type: EXPERIMENTAL
Intervention: Total homocysteine (tHcy) as a continuous variable
Number of subjects: 840
Study 15354908 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer/fluoride liquid dentifrice
Number of subjects: 19
Study 15354908 — intervention group
Group type: COMPARATOR
Intervention: Fluoride-containing traditional control toothpaste
Number of subjects: 19
Study 12131319 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin substitution
Number of subjects: 20
Study 12131319 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonwarfarin treated patients)
Number of subjects: 20
Study 9817273 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/m2 amifostine intravenously before HD-RIT
Number of subjects: 50
Study 9817273 — intervention group
Group type: COMPARATOR
Intervention: Physiologic saline solution (Control)
Number of subjects: 50
Study 7656141 — intervention group
Group type: EXPERIMENTAL
Intervention: High humidity environment
Number of subjects: 10
Study 7656141 — intervention group
Group type: COMPARATOR
Intervention: Normal humidity environment
Number of subjects: 10
Study 7656141 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic saline (0.9%)
Number of subjects: 10
Study 7656141 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (1.5%)
Number of subjects: 10
Study 2468978 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% pentastarch (group P)
Number of subjects: 94
Study 2468978 — intervention group
Group type: COMPARATOR
Intervention: 5% albumin (group A)
Number of subjects: 94
Study 330440 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofepramine
Number of subjects: 0
Study 330440 — intervention group
Group type: COMPARATOR
Intervention: Maprotiline
Number of subjects: 0
Study 31151486 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative immunonutrition
Number of subjects: 96
Study 31151486 — intervention group
Group type: COMPARATOR
Intervention: Control (historical)
Number of subjects: 96
Study 28079825 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium 0.6 mg/kg administered at loss of eyelash reflex (Control group C; n=45)
Number of subjects: 135
Study 28079825 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg administered when BIS fell to less than 40 (Experimental group T; n=45)
Number of subjects: 135
Study 28079825 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg administered when BIS fell below 40 after manual ventilation with sevoflurane (Experimental group S; n=45)
Number of subjects: 135
Study 25014236 — intervention group
Group type: EXPERIMENTAL
Intervention: Digestive Symptom Frequency Questionnaire (DSFQ)
Number of subjects: 200
Study 24002321 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological intervention (supportive and psycho-educational sessions with a neuropsychologist)
Number of subjects: 86
Study 24002321 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 86
Study 21819167 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal hypertension intervention
Number of subjects: 283
Study 21819167 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 283
Study 19414236 — intervention group
Group type: EXPERIMENTAL
Intervention: Positively enhanced dosed exposure (PDE)
Number of subjects: 39
Study 19414236 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosed-only exposure (DE)
Number of subjects: 39
Study 19414236 — intervention group
Group type: COMPARATOR
Intervention: Prolonged exposure (PE)
Number of subjects: 39
Study 19414236 — intervention group
Group type: COMPARATOR
Intervention: Negatively-supplemented dosed exposure (NDE)
Number of subjects: 39
Study 17548726 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic interval training (95% of peak heart rate) 3 times per week for 12 weeks
Number of subjects: 27
Study 17548726 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate continuous training (70% of highest measured heart rate) 3 times per week for 12 weeks
Number of subjects: 27
Study 17548726 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard advice regarding physical activity)
Number of subjects: 27
Study 14627997 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (DMI)
Number of subjects: 0
Study 14627997 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0
Study 14627997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11685593 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days' intravenous antibiotics (group A)
Number of subjects: 92
Study 11685593 — intervention group
Group type: COMPARATOR
Intervention: 3 days' intravenous antibiotics (group B)
Number of subjects: 92
Study 9457458 — intervention group
Group type: EXPERIMENTAL
Intervention: Carteolol 2% and pilocarpine 2% (CBS341A)
Number of subjects: 209
Study 9457458 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% and pilocarpine 2%
Number of subjects: 209
Study 8186347 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg/day for 3 days
Number of subjects: 24
Study 8186347 — intervention group
Group type: COMPARATOR
Intervention: No-drug control period
Number of subjects: 24
Study 3369330 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo injections with strict surveillance of alcohol intake
Number of subjects: 70
Study 3369330 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo injections without surveillance
Number of subjects: 70
Study 3369330 — intervention group
Group type: COMPARATOR
Intervention: No placebo injections with surveillance
Number of subjects: 70
Study 3369330 — intervention group
Group type: COMPARATOR
Intervention: No placebo injections without surveillance
Number of subjects: 70
Study 30550515 — intervention group
Group type: EXPERIMENTAL
Intervention: RERmax ≥1.10
Number of subjects: 83
Study 30550515 — intervention group
Group type: EXPERIMENTAL
Intervention: HRmax ≥95% of age‐predicted HRmax
Number of subjects: 83
Study 30550515 — intervention group
Group type: EXPERIMENTAL
Intervention: RPEmax ≥19
Number of subjects: 83
Study 30550515 — intervention group
Group type: EXPERIMENTAL
Intervention: BLmax ≥8 mmol·L
Number of subjects: 83
Study 30550515 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraclass correlation for RERmax
Number of subjects: 83
Study 30550515 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraclass correlation for HRmax
Number of subjects: 83
Study 30550515 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraclass correlation for BLmax
Number of subjects: 83
Study 30052722 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (HIV prevention intervention)
Number of subjects: 0
Study 30052722 — intervention group
Group type: COMPARATOR
Intervention: Control group (no direct intervention)
Number of subjects: 0
Study 26348533 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of olodaterol (0.5-25 μg)
Number of subjects: 148
Study 26348533 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral inhalation of olodaterol (2.5-70 μg via Respimat® inhaler)
Number of subjects: 148
Study 25292398 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic medication treatment
Number of subjects: 86
Study 22452975 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory oxygen during pulmonary rehabilitation (PR)
Number of subjects: 51
Study 22452975 — intervention group
Group type: COMPARATOR
Intervention: Room air during pulmonary rehabilitation (PR)
Number of subjects: 51
Study 22452975 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory oxygen during PR
Number of subjects: 51
Study 22452975 — intervention group
Group type: COMPARATOR
Intervention: Room air during PR
Number of subjects: 51
Study 20943455 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Pringle maneuver and ischemic preconditioning followed by continuous Pringle maneuver
Number of subjects: 0
Study 20943455 — intervention group
Group type: COMPARATOR
Intervention: Intermittent Pringle maneuver
Number of subjects: 0
Study 20943455 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning
Number of subjects: 0
Study 20943455 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemihepatic vascular occlusion
Number of subjects: 0
Study 20943455 — intervention group
Group type: COMPARATOR
Intervention: Total hepatic vascular exclusion (THVE)
Number of subjects: 0
Study 20943455 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective hepatic vascular exclusion (SHVE)
Number of subjects: 0
Study 17981449 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (1.84 g/day of EPA and DHA)
Number of subjects: 59
Study 17981449 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn oil with 1% fish oil)
Number of subjects: 59
Study 16439505 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-crosslinked hyaluronan gel
Number of subjects: 52
Study 16439505 — intervention group
Group type: COMPARATOR
Intervention: No adhesion prevention (Control)
Number of subjects: 52
Study 11880820 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical Optimal Cadence (MOC, 90 rpm)
Number of subjects: 8
Study 11880820 — intervention group
Group type: EXPERIMENTAL
Intervention: Freely Chosen Cadence (FCC, 81.2 +/- 7.2 rpm)
Number of subjects: 8
Study 11880820 — intervention group
Group type: EXPERIMENTAL
Intervention: Energetically Optimal Cadence (EOC, 72.5 +/- 4.6 rpm)
Number of subjects: 8
Study 11880820 — intervention group
Group type: COMPARATOR
Intervention: Isolated Run (IR)
Number of subjects: 8
Study 9446844 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women consuming 450 microg folate/d
Number of subjects: 24
Study 9446844 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women consuming 850 microg folate/d
Number of subjects: 24
Study 9446844 — intervention group
Group type: COMPARATOR
Intervention: Nonpregnant controls
Number of subjects: 24
Study 8556899 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 78
Study 8556899 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with psychosocial stimulation
Number of subjects: 78
Study 8556899 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study 2118417 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide and flutamide
Number of subjects: 603
Study 2118417 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide alone
Number of subjects: 603
Study 727887 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadyl acetate
Number of subjects: 636
Study 727887 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 636
Study 30779529 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus Axitinib
Number of subjects: 861
Study 30779529 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 861
Study 28965868 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy food consumption education and discount coupons for healthy food
Number of subjects: 0
Study 28965868 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 25869827 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 68
Study 25869827 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoanalytic psychotherapy (PPT)
Number of subjects: 68
Study 25547983 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet rich plasma (PRP) treatment
Number of subjects: 150
Study 25547983 — intervention group
Group type: COMPARATOR
Intervention: Standard moist wound care (Control)
Number of subjects: 150
Study 22482969 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve-sparing radical hysterectomy (NRH)
Number of subjects: 30
Study 22482969 — intervention group
Group type: COMPARATOR
Intervention: Conventional radical hysterectomy (RH)
Number of subjects: 30
Study 20093333 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic ECC (open modification)
Number of subjects: 54
Study 20093333 — intervention group
Group type: COMPARATOR
Intervention: Mini-ECC
Number of subjects: 54
Study 18416281 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (250, 500, or 1000 mg, single dose) after acetylsalicylic acid (aspirin)
Number of subjects: 6
Study 18416281 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (twice daily for 4 days) with aspirin administered with the penultimate dose
Number of subjects: 6
Study 18416281 — intervention group
Group type: COMPARATOR
Intervention: Levetiracetam (twice daily for 4.5 days)
Number of subjects: 6
Study 18416281 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice daily for 4.5 days)
Number of subjects: 6
Study 15903357 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly designed physical training program (EG)
Number of subjects: 1967
Study 15903357 — intervention group
Group type: COMPARATOR
Intervention: Traditional Basic Combat Training physical training program (CG)
Number of subjects: 1967
Study 16958742 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin probe (54 mm handle diameter)
Number of subjects: 11
Study 16958742 — intervention group
Group type: COMPARATOR
Intervention: Thick probe (92 mm handle diameter)
Number of subjects: 11
Study 10482690 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileocecal interpositional graft placement
Number of subjects: 14
Study 8872417 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/day of tacrine
Number of subjects: 0
Study 8872417 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/day of tacrine
Number of subjects: 0
Study 8872417 — intervention group
Group type: EXPERIMENTAL
Intervention: tacrine (dosage not specified) with lecithin
Number of subjects: 0
Study 8872417 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 1804294 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoralen plus ultraviolet A (PUVA) therapy, oral psoralen (8‐methoxypsoralen; 0.6 mg/kg) taken at each session, 10-20 sessions 3 times per week
Number of subjects: 83
Study 1804294 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoralen plus ultraviolet A (PUVA) therapy
Number of subjects: 83
Study 6318347 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi‐Profenid 150 mg
Number of subjects: 25
Study 6318347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 31980156 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-hamstring local anaesthetic injection (Group H)
Number of subjects: 105
Study 31980156 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior division obturator nerve block (Group O)
Number of subjects: 105
Study 31980156 — intervention group
Group type: COMPARATOR
Intervention: Adductor canal block alone (Group C)
Number of subjects: 105
Study 31980156 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (H, O, C)
Number of subjects: 105
Study 30935601 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive power toothbrush (Oral-B Professional Care 6000, D36/EB20) with Bluetooth technology
Number of subjects: 60
Study 30935601 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush (Oral-B Indicator 35 soft)
Number of subjects: 60
Study 31185747 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of personal technology (smartphones, internet, personal email)
Number of subjects: 320
Study 31185747 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning about HIV education via the internet
Number of subjects: 320
Study 31185747 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of internet use for HIV prevention
Number of subjects: 320
Study 26861604 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus bevacizumab
Number of subjects: 374
Study 26861604 — intervention group
Group type: COMPARATOR
Intervention: FOLFOXIRI
Number of subjects: 374
Study 24886027 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmentally Adapted Cognitive Processing Therapy (D-CPT)
Number of subjects: 90
Study 24886027 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 90
Study 22867036 — intervention group
Group type: COMPARATOR
Intervention: Placebo pill plus behavioral support
Number of subjects: 184
Study 20168306 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (240 mg/day)
Number of subjects: 3069
Study 20168306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3069
Study 18617314 — intervention group
Group type: EXPERIMENTAL
Intervention: 30:2 compression:ventilation (C:V) ratio
Number of subjects: 80
Study 18617314 — intervention group
Group type: COMPARATOR
Intervention: 15:2 compression:ventilation (C:V) ratio
Number of subjects: 80
Study 16143705 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg
Number of subjects: 100
Study 16143705 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin 10 mg
Number of subjects: 100
Study 16143705 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg
Number of subjects: 100
Study 16143705 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin 20 mg
Number of subjects: 100
Study 16143705 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Number of subjects: 100
Study 12804793 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive viscous force field cued by blue color
Number of subjects: 0
Study 12804793 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistive viscous force field cued by red color
Number of subjects: 0
Study 12804793 — intervention group
Group type: EXPERIMENTAL
Intervention: Random presentation of two force fields
Number of subjects: 0
Study 10574423 — intervention group
Group type: EXPERIMENTAL
Intervention: ramipril-felodipine ER (10/10 mg)
Number of subjects: 507
Study 10574423 — intervention group
Group type: EXPERIMENTAL
Intervention: ramipril-felodipine ER (5/5 mg)
Number of subjects: 507
Study 10574423 — intervention group
Group type: COMPARATOR
Intervention: felodipine ER monotherapy
Number of subjects: 507
Study 8834347 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral airway occlusion at residual volume (RV)
Number of subjects: 8
Study 8834347 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral airway occlusion at total lung capacity (TLC)
Number of subjects: 8
Study 8834347 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral airway occlusion
Number of subjects: 8
Study 1865280 — intervention group
Group type: EXPERIMENTAL
Intervention: alanine ORS
Number of subjects: 129
Study 1865280 — intervention group
Group type: COMPARATOR
Intervention: WHO‐ORS
Number of subjects: 129
Study 30336946 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume‐controlled ventilation with inspiratory flow of 20 lpm (VC‐CMV20)
Number of subjects: 30
Study 30336946 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure support ventilation (PSV)
Number of subjects: 30
Study 30336946 — intervention group
Group type: COMPARATOR
Intervention: Target peak pressure of 40 cmH2O
Number of subjects: 30
Study 28393853 — intervention group
Group type: EXPERIMENTAL
Intervention: Authentication of physical keys using optical multiple-scattering media and coherent states of light.
Number of subjects: 0
Study 25304277 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival preparation of 6×6 mm (group A)
Number of subjects: 28
Study 25304277 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival preparation of 8×9 mm (group B)
Number of subjects: 28
Study 23150151 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 loss-of-function alleles
Number of subjects: 670
Study 23150151 — intervention group
Group type: COMPARATOR
Intervention: ABCB1 genotype
Number of subjects: 670
Study 23150151 — intervention group
Group type: COMPARATOR
Intervention: PON1 genotype
Number of subjects: 670
Study 23150151 — intervention group
Group type: COMPARATOR
Intervention: CYP2C19, ABCB1, and PON1 genotypes
Number of subjects: 670
Study 21684018 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-camera delivered cognitive-behavioral therapy (W-CBT)
Number of subjects: 31
Study 21684018 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 31
Study 20162114 — intervention group
Group type: EXPERIMENTAL
Intervention: BCP (biphasic calcium phosphate)
Number of subjects: 11
Study 20162114 — intervention group
Group type: COMPARATOR
Intervention: DBB (deproteinized bovine bone)
Number of subjects: 11
Study 18008156 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant FSH commenced in the luteal phase with a long GnRH agonist protocol
Number of subjects: 42
Study 18008156 — intervention group
Group type: COMPARATOR
Intervention: Control group received FSH on day 2 in a short protocol GnRH agonist regimen
Number of subjects: 42
Study 15564545 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial-artery grafts
Number of subjects: 561
Study 15564545 — intervention group
Group type: COMPARATOR
Intervention: Saphenous-vein grafts
Number of subjects: 561
Study 11278211 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganirelix (0.25 mg, s.c.)
Number of subjects: 236
Study 11278211 — intervention group
Group type: COMPARATOR
Intervention: Triptorelin (0.1 mg, s.c.)
Number of subjects: 236